3361Core questions on household energy use: module 4: monitoring and evaluationTechnical Documents · 25 août 2022
3362Surveillance, case investigation and contact tracing for monkeypox: interim guidance, 25 August 2022Technical Documents · 25 août 2022
3363Turning down the alcohol flow. Background document on the European framework for action on alcohol, 2022–2025Technical Documents · 25 août 2022
3364COVID-19 weekly epidemiological update, edition 106, 24 August 2022Technical Documents · 24 août 2022
3365War in Ukraine: situation report from WHO Ukraine country office. Issue No.20, 24 August 2022Technical Documents · 24 août 2022
3366Vaccines and immunization for monkeypox: interim guidance, 24 August 2022Technical Documents · 24 août 2022
3367Preventing antimicrobial resistance and promoting appropriate antimicrobial use in inpatient health care in Greece: EVIPNet evidence brief for policy, number 10Technical Documents · 23 août 2022
3368Evidence-informed policy to tackle childhood cancer in Uzbekistan: a narrative case studyTechnical Documents · 22 août 2022
3369Руководство для НТКГИ по адаптированному Процессу разработки рекомендаций на основе доказательных данныхTechnical Documents · 22 août 2022
3370Предварительные рекомендации по применению вакцины CanSinoBIO Ad5-nCoV-S [рекомбинантной] (Convidecia™) против COVID-19: Временное руководство (Первый выпуск 19 мая 2022 г.)Technical Documents · 19 août 2022
3371Annexes to the recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: grading of evidence: evidence to recommendation tables, first issuance: 3 February 2021 (included in the background document), updated 15 June 2021, updated: 19 November 2021, updated: 23 February 2022, updated 18 August 2022Technical Documents · 18 août 2022
3372Annexes to the recommendations for use of the Valneva VLA2001 vaccine against COVID 19: grading of evidence: evidence to recommendations tables, first issued 18 August 2022Technical Documents · 18 août 2022
3373WHO European Centre for Primary Health Care: annual report 2020–2021Technical Documents · 18 août 2022
3374Background to the recommendations for use of the Valneva VLA2001 vaccine against COVID 19: background document to the WHO: interim recommendations for use of the Valneva vaccine VLA2001 against COVID-19, 18 August 2022Technical Documents · 18 août 2022
3375Good practice statement on the use of second booster doses for COVID 19 vaccines, 18 August 2022Technical Documents · 18 août 2022
3376Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19: grading of evidence - evidence to recommendation tables, first issued 14 January 2021 (included in the background document), updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022Technical Documents · 18 août 2022
3377Interim recommendations for use of the Valneva VLA2001 vaccine against COVID 19: interim guidance, first issued 18 August 2022Technical Documents · 18 août 2022
3378Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022Technical Documents · 18 août 2022
3379Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, first issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022Technical Documents · 18 août 2022
3380Fifteenth Meeting of the WHO European Action Network on Reducing Marketing Pressure on Children, 19 May 2021: meeting reportTechnical Documents · 18 août 2022